Aktuellt
SENASTE
Redeye returns with a more in-depth take on BONESUPPORT’s Q4-report following the conference call and management discussion. We are prone to minor downwards adjustments to our sales expectations in the coming quarters, though non-affecting our Base Case, which entails a c.80% upside potential. We believe the stock could soon be re-ignited by a potential FDA approval in the coming weeks.
LÄS MER
